Evaluation of Growth Characteristics and Final Height of Cases Diagnosed with Noonan Syndrome on Growth Hormone Treatment

• Published in: Journal of clinical research in pediatric endocrinology Vol. 17; no. 1; pp. 76 - 86
• Main Authors: Şıklar, Zeynep, Berberoğlu, Merih, Kızılcan Çetin, Sirmen, Yıldız, Melek, Turan, Serap, Darcan, Şükran, Çetinkaya, Semra, Hatipoğlu, Nihal, Yıldırım, Ruken, Demir, Korcan, Vermezoğlu, Öznur, Yavaş Abalı, Zehra, Özalp Kızılay, Deniz, Görkem Erdoğan, Nilay, Şiraz, Ülkü Gül, Orbak, Zerrin, Özgen, İlker Tolga, Bideci, Aysun, Selver Eklioğlu, Beray, Karakılıç Özturan, Esin, Tarçın, Gürkan, Bereket, Abdullah, Darendeliler, Feyza
• Format: Journal Article
• Language: English
• Published: Turkey Galenos Publishing House 01.03.2025; Galenos Publishing; Galenos Yayincilik
• Subjects: Adolescent; Age; Body Height - drug effects; Body mass index; Child; Child, Preschool; Children & youth; Diabetes; Endocrinology; Female; final height; Follow-Up Studies; Growth Disorders - drug therapy; Growth Disorders - etiology; Growth Disorders - physiopathology; growth hormone; Growth hormones; Human Growth Hormone - administration & dosage; Human Growth Hormone - adverse effects; Humans; Kinases; Male; Mutation; noonan syndrome; Noonan Syndrome - complications; Noonan Syndrome - drug therapy; Noonan Syndrome - physiopathology; Original; Patients; Pediatrics; Population; Puberty; Retrospective Studies; Teenagers; treatment; Treatment Outcome; treatment; growth hormone; Final height; Noonan syndrome
• ISSN: 1308-5727; 1308-5735; 1308-5735
• DOI: 10.4274/jcrpe.galenos.2024.2024-7-3

Proportional short stature is one of the most important features of Noonan syndrome (NS), and adult height often remains below the third percentile. Although the pathophysiology of short stature in NS patients is not fully understood, it has been shown that growth hormone (GH) treatment is beneficial in NS, significantly improving height in respect to the results of short and long-term GH treatment. In this national retrospective cohort study, patients with NS who reached final height from 14 centers were evaluated. Patients were stratified by sex and treatment with or without GH and final height outcomes were compared. The study included 67 patients with NS, of whom 53 (79.1%) with mean follow-up 5.6 years, received GH treatment. At presentation height standard deviation scores (SDS) of the subjects who were started on GH tended to be shorter than those who did not (-3.26±1.07 vs. -2.53±1.23). In girls mean final height and final height SDS in those using GH vs not using GH were 150.1 cm (-2.17 SDS) vs. 147.4 cm (-2.8 SDS), respectively, and for boys these values were 162.48 cm (-1.81 SDS) vs 157.46 cm (-2.68 SDS), respectively. The Δheight SDS value of the cases was significantly higher in the group receiving GH compared to those not receiving GH (1.36±1.12 SD vs. -0.2±1.24, p<0.001). Cardiac findings remained stable in two patients with hypertrophic cardiomyopathy who received GH treatment. No significant side effects were observed in any patient during follow-up. In patients with NS who reach their final height, a significant increase in height was observed with GH treatment. An increase of approximately +1.4 SDS may be achieved. GH treatment appears to be safe and effective in NS.